[S02DA03, antipyrine, The therapeutic efficacy of Selexipag can be decreased when used in combination with Antipyrine.]
[B01AD01, streptokinase, Streptokinase may increase the hypotensive activities of Selexipag.]
[J01EC02, sulfadiazine, The metabolism of Selexipag can be decreased when combined with Sulfadiazine.]
[M01AB02, sulindac, The therapeutic efficacy of Selexipag can be decreased when used in combination with Sulindac.]
[M01AX04, apazone, The therapeutic efficacy of Selexipag can be decreased when used in combination with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Selexipag can be decreased when combined with Tamoxifen.]
[R03CC03, terbutaline, Terbutaline may decrease the antihypertensive activities of Selexipag.]
[B01AE07, dabigatran etexilate, The serum concentration of Selexipag can be increased when it is combined with Dabigatran etexilate.]
[N05AE05, lurasidone, Lurasidone may decrease the antihypertensive activities of Selexipag.]
[N04BC07, apomorphine, The metabolism of Selexipag can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, Thalidomide may increase the hypotensive activities of Selexipag.]
[R03DA04, theophylline, The metabolism of Selexipag can be decreased when combined with Theophylline.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Selexipag.]
[N05AB08, thioproperazine, Thioproperazine may decrease the antihypertensive activities of Selexipag.]
[N05AC02, thioridazine, Thioridazine may decrease the antihypertensive activities of Selexipag.]
[G04BE06, moxisylyte, Moxisylyte may decrease the antihypertensive activities of Selexipag.]
[B01AC05, ticlopidine, The metabolism of Selexipag can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, Timolol may increase the hypotensive activities of Selexipag.]
[M02AX02, tolazoline, Tolazoline may decrease the antihypertensive activities of Selexipag.]
[V04CA01, tolbutamide, The metabolism of Selexipag can be decreased when combined with Tolbutamide.]
[M02AA21, tolmetin, The therapeutic efficacy of Selexipag can be decreased when used in combination with Tolmetin.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypotensive activities of Selexipag.]
[N06AX05, trazodone, Trazodone may decrease the antihypertensive activities of Selexipag.]
[L01XF01, tretinoin, The metabolism of Selexipag can be decreased when combined with Tretinoin.]
[C03DB02, triamterene, Triamterene may increase the hypotensive activities of Selexipag.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Selexipag can be increased when used in combination with Trichlormethiazide.]
[N05AB06, trifluoperazine, Trifluoperazine may decrease the antihypertensive activities of Selexipag.]
[R03BA07, mometasone, The metabolism of Selexipag can be decreased when combined with Mometasone.]
[S01ED04, metipranolol, Metipranolol may increase the hypotensive activities of Selexipag.]
[N03AC02, trimethadione, The metabolism of Selexipag can be decreased when combined with Trimethadione.]
[C02BA01, trimethaphan, Trimethaphan may increase the hypotensive activities of Selexipag.]
[J01EA01, trimethoprim, The metabolism of Selexipag can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Selexipag.]
[J01FA08, troleandomycin, The metabolism of Selexipag can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, Vilazodone may decrease the antihypertensive activities of Selexipag.]
[C09CA09, azilsartan medoxomil, Azilsartan medoxomil may increase the hypotensive activities of Selexipag.]
[L01EX04, vandetanib, The serum concentration of Selexipag can be increased when it is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Selexipag can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Selexipag can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Selexipag can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Selexipag can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Selexipag can be decreased when combined with Rilpivirine.]
[B01AF01, rivaroxaban, The serum concentration of Selexipag can be increased when it is combined with Rivaroxaban.]
[R03AC18, indacaterol, The serum concentration of Selexipag can be increased when it is combined with Indacaterol.]
[B01AC24, ticagrelor, The serum concentration of Selexipag can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Selexipag can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Selexipag can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Selexipag.]
[C04AX07, vincamine, Selexipag may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The serum concentration of Vincristine can be increased when it is combined with Selexipag.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Selexipag.]
[C03BA10, xipamide, Selexipag may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The metabolism of Selexipag can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, Zuclopenthixol may decrease the antihypertensive activities of Selexipag.]
[J05AE02, indinavir, The metabolism of Selexipag can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Selexipag can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Selexipag.]
[L01ED01, crizotinib, The metabolism of Selexipag can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, Ziprasidone may increase the antihypertensive activities of Selexipag.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the antihypertensive activities of Selexipag.]
[C07AB03, atenolol, Atenolol may increase the hypotensive activities of Selexipag.]
[L01FA01, rituximab, Selexipag may increase the hypotensive activities of Rituximab.]
[J02AC03, voriconazole, The metabolism of Selexipag can be decreased when combined with Voriconazole.]
[S01FA01, atropine, Atropine may decrease the antihypertensive activities of Selexipag.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Selexipag.]
[R07AX02, ivacaftor, The serum concentration of Selexipag can be increased when it is combined with Ivacaftor.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Selexipag.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Selexipag.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Selexipag.]
[G04BD12, mirabegron, The serum concentration of Selexipag can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Selexipag can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Selexipag can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Selexipag can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Selexipag can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Selexipag can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The metabolism of Selexipag can be decreased when combined with Teriflunomide.]
[C01CA18, octopamine, Octopamine may decrease the antihypertensive activities of Selexipag.]
[L01EX05, regorafenib, The serum concentration of Selexipag can be increased when it is combined with Regorafenib.]
[J05AE04, nelfinavir, The metabolism of Selexipag can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Selexipag.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Selexipag.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Selexipag.]
[C08CA13, lercanidipine, Lercanidipine may increase the hypotensive activities of Selexipag.]
[N02CC03, zolmitriptan, Zolmitriptan may decrease the antihypertensive activities of Selexipag.]
[N01AA01, ethyl ether, Diethyl ether may decrease the antihypertensive activities of Selexipag.]
[L01EX07, cabozantinib, The metabolism of Selexipag can be decreased when combined with Cabozantinib.]
[G04BE03, sildenafil, The serum concentration of Selexipag can be increased when it is combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Selexipag.]
[B01AF02, apixaban, The metabolism of Selexipag can be decreased when combined with Apixaban.]
[C10AX12, lomitapide, The serum concentration of Selexipag can be increased when it is combined with Lomitapide.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Selexipag can be increased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Selexipag.]
[N02BA10, benorilate, The therapeutic efficacy of Selexipag can be decreased when used in combination with Benorilate.]
[A10BK02, canagliflozin, The serum concentration of Selexipag can be increased when it is combined with Canagliflozin.]
[M04AB03, benzbromarone, The excretion of Selexipag can be decreased when combined with Benzbromarone.]
[A06AX06, tegaserod, The serum concentration of Selexipag can be increased when it is combined with Tegaserod.]
[J02AX04, caspofungin, The excretion of Selexipag can be decreased when combined with Caspofungin.]
[M01AH01, celecoxib, The therapeutic efficacy of Selexipag can be decreased when used in combination with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may decrease the antihypertensive activities of Selexipag.]
[L04AA18, everolimus, The serum concentration of Selexipag can be increased when it is combined with Everolimus.]
[L01EC02, dabrafenib, The serum concentration of Selexipag can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The therapeutic efficacy of Selexipag can be decreased when used in combination with Benzydamine.]
[L01EE01, trametinib, The metabolism of Selexipag can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The metabolism of Selexipag can be decreased when combined with Benzyl alcohol.]
[L01EB03, afatinib, The serum concentration of Selexipag can be increased when it is combined with Afatinib.]
[N06AX28, levomilnacipran, The metabolism of Selexipag can be decreased when combined with Levomilnacipran.]
[J05AJ03, dolutegravir, The serum concentration of Selexipag can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, Bepridil may increase the hypotensive activities of Selexipag.]
[C02KX05, riociguat, The metabolism of Selexipag can be decreased when combined with Riociguat.]
[A05AA03, cholic acid, The excretion of Selexipag can be increased when combined with Cholic Acid.]
[C02KX04, macitentan, Macitentan may increase the hypotensive activities of Selexipag.]
[N06AX26, vortioxetine, The metabolism of Selexipag can be decreased when combined with Vortioxetine.]
[J05AP05, simeprevir, The metabolism of Selexipag can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Selexipag can be increased when it is combined with Sofosbuvir.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the hypotensive activities of Selexipag.]
[C01CA27, droxidopa, Droxidopa may decrease the antihypertensive activities of Selexipag.]
[C07AB04, acebutolol, Acebutolol may increase the hypotensive activities of Selexipag.]
[A16AA07, metreleptin, The metabolism of Selexipag can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Selexipag can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The metabolism of Selexipag can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, Betaxolol may increase the hypotensive activities of Selexipag.]
[C02CC01, bethanidine, Bethanidine may decrease the antihypertensive activities of Selexipag.]
[C10AB02, bezafibrate, The metabolism of Selexipag can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Selexipag can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Selexipag.]
[B01AC26, vorapaxar, The serum concentration of Selexipag can be increased when it is combined with Vorapaxar.]
[L01XH04, belinostat, The serum concentration of Selexipag can be increased when it is combined with Belinostat.]
[L01EM01, idelalisib, The serum concentration of Selexipag can be increased when it is combined with Idelalisib.]
[A10BK03, empagliflozin, Empagliflozin may increase the hypotensive activities of Selexipag.]
[R03AC19, olodaterol, The metabolism of Selexipag can be decreased when combined with Olodaterol.]
[S01EE02, unoprostone, Unoprostone may increase the hypotensive activities of Selexipag.]
[N05CM19, suvorexant, The serum concentration of Selexipag can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Selexipag can be increased when it is combined with Eliglustat.]
[N05AA04, acepromazine, Acepromazine may decrease the antihypertensive activities of Selexipag.]
[L01EX09, nintedanib, The serum concentration of Selexipag can be increased when it is combined with Nintedanib.]
[J05AP09, dasabuvir, The metabolism of Selexipag can be decreased when combined with Dasabuvir.]
[B01AF03, edoxaban, The serum concentration of Selexipag can be increased when it is combined with Edoxaban.]
[N06AX11, mirtazapine, Mirtazapine may decrease the antihypertensive activities of Selexipag.]
[L04AC10, secukinumab, The metabolism of Selexipag can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Selexipag can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Selexipag can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Selexipag.]
[J05AP07, daclatasvir, The serum concentration of Selexipag can be increased when it is combined with Daclatasvir.]
[J05AP06, asunaprevir, The serum concentration of Selexipag can be increased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The excretion of Selexipag can be decreased when combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may decrease the antihypertensive activities of Selexipag.]
[A04AD14, rolapitant, The serum concentration of Selexipag can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Selexipag can be increased when it is combined with Flibanserin.]
[N05AX15, cariprazine, Cariprazine may decrease the antihypertensive activities of Selexipag.]
[M02AA25, aceclofenac, The therapeutic efficacy of Selexipag can be decreased when used in combination with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Selexipag can be decreased when used in combination with Acemetacin.]
[A02BC03, lansoprazole, The metabolism of Selexipag can be decreased when combined with Lansoprazole.]
[J02AC05, isavuconazole, The serum concentration of Selexipag can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Selexipag.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Selexipag.]
[S01AA13, fusidic acid, The metabolism of Selexipag can be decreased when combined with Fusidic acid.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Selexipag.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Selexipag.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Selexipag.]
[M01AE16, alminoprofen, The therapeutic efficacy of Selexipag can be decreased when used in combination with Alminoprofen.]
[L01XX52, venetoclax, The metabolism of Selexipag can be decreased when combined with Venetoclax.]
[N04BC01, bromocriptine, Bromocriptine may decrease the antihypertensive activities of Selexipag.]
[N06AA19, amineptin, Amineptine may decrease the antihypertensive activities of Selexipag.]
[C08CA01, amlodipine, Amlodipine may increase the hypotensive activities of Selexipag.]
[C03CA02, bumetanide, Bumetanide may increase the hypotensive activities of Selexipag.]
[N01BB01, bupivacaine, Bupivacaine may increase the hypotensive activities of Selexipag.]
[C07AA19, bupranolol, Bupranolol may increase the hypotensive activities of Selexipag.]
[N07BC01, buprenorphine, The metabolism of Selexipag can be decreased when combined with Buprenorphine.]
[N05BE01, buspirone, Buspirone may decrease the antihypertensive activities of Selexipag.]
[L01XX27, arsenic trioxide, The serum concentration of Selexipag can be increased when it is combined with Arsenic trioxide.]
[S01GX07, azelastine, The metabolism of Selexipag can be decreased when combined with Azelastine.]
[L01EF02, ribociclib, The metabolism of Selexipag can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The therapeutic efficacy of Selexipag can be decreased when used in combination with Balsalazide.]
[R03CC12, bambuterol, Bambuterol may decrease the antihypertensive activities of Selexipag.]
[C09AA07, benazepril, Benazepril may increase the hypotensive activities of Selexipag.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Selexipag.]
[J05AE09, tipranavir, The metabolism of Selexipag can be decreased when combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Selexipag can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Selexipag can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Selexipag.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Selexipag.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Selexipag.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Selexipag.]
[L01EH02, neratinib, The serum concentration of Selexipag can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Selexipag.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Selexipag.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Selexipag.]
[C07AB07, bisoprolol, The serum concentration of Selexipag can be increased when it is combined with Bisoprolol.]
[R03AC17, bitolterol, Bitolterol may decrease the antihypertensive activities of Selexipag.]
[J05AG03, efavirenz, The metabolism of Selexipag can be decreased when combined with Efavirenz.]
[C01DX19, nesiritide, Nesiritide may increase the hypotensive activities of Selexipag.]
[V03AB23, acetylcysteine, The excretion of Selexipag can be decreased when combined with Acetylcysteine.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Selexipag.]
[M01AB07, bumadizone, The therapeutic efficacy of Selexipag can be decreased when used in combination with Bumadizone.]
[J05AX18, letermovir, The metabolism of Selexipag can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, Butriptyline may decrease the antihypertensive activities of Selexipag.]
[A10BK04, ertugliflozin, The serum concentration of Ertugliflozin can be increased when it is combined with Selexipag.]
[C09AA01, captopril, Captopril may increase the hypotensive activities of Selexipag.]
[L02BB05, apalutamide, The serum concentration of Selexipag can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Selexipag can be increased when combined with Carbamazepine.]
[C07AG02, carvedilol, The serum concentration of Selexipag can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Selexipag.]
[N03AX24, cannabidiol, The metabolism of Selexipag can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Selexipag.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Selexipag.]
[C07AB08, celiprolol, Celiprolol may increase the hypotensive activities of Selexipag.]
[H01CC03, elagolix, The serum concentration of Selexipag can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Selexipag can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Selexipag can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Selexipag.]
[J05AX24, tecovirimat, The metabolism of Selexipag can be increased when combined with Tecovirimat.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Selexipag.]
[L01EB07, dacomitinib, The serum concentration of Selexipag can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Selexipag can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Selexipag.]
[M01AC05, lornoxicam, The therapeutic efficacy of Selexipag can be decreased when used in combination with Lornoxicam.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Selexipag.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Selexipag.]
[L04AA39, emapalumab, The metabolism of Selexipag can be increased when combined with Emapalumab.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Selexipag.]
[L01EX13, gilteritinib, The serum concentration of Gilteritinib can be increased when it is combined with Selexipag.]
[L01XJ03, glasdegib, The serum concentration of Selexipag can be increased when it is combined with Glasdegib.]
[C09AA08, cilazapril, Cilazapril may increase the hypotensive activities of Selexipag.]
[A03FA08, cinitapride, Cinitapride may decrease the antihypertensive activities of Selexipag.]
[S01ED05, carteolol, Carteolol may increase the hypotensive activities of Selexipag.]
[P02BX04, triclabendazole, The metabolism of Selexipag can be decreased when combined with Triclabendazole.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Selexipag.]
[J01FA09, clarithromycin, The metabolism of Selexipag can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Solriamfetol may decrease the antihypertensive activities of Selexipag.]
[L01EN01, erdafitinib, The serum concentration of Selexipag can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Selexipag can be increased when it is combined with Clobazam.]
[C09CA06, candesartan, The metabolism of Selexipag can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Selexipag can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The metabolism of Selexipag can be decreased when combined with Alpelisib.]
[L01XX66, selinexor, The excretion of Selexipag can be decreased when combined with Selinexor.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Selexipag.]
[L01EX15, pexidartinib, The excretion of Selexipag can be decreased when combined with Pexidartinib.]
[C03BX03, cicletanine, Selexipag may increase the hypotensive activities of Cicletanine.]
[L01EJ02, fedratinib, The serum concentration of Selexipag can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Selexipag can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Selexipag can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, The serum concentration of Lefamulin can be increased when it is combined with Selexipag.]
[N04CX01, istradefylline, The serum concentration of Selexipag can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Selexipag can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the antihypertensive activities of Selexipag.]
[J01XX09, daptomycin, The serum concentration of Selexipag can be increased when it is combined with Daptomycin.]
[N02CC08, lasmiditan, The serum concentration of Selexipag can be increased when it is combined with Lasmiditan.]
[N03AX25, cenobamate, The serum concentration of Selexipag can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Selexipag.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Selexipag.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Selexipag.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Selexipag.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Selexipag.]
[C10AX15, bempedoic acid, The excretion of Selexipag can be decreased when combined with Bempedoic acid.]
[J05AB16, remdesivir, The excretion of Selexipag can be decreased when combined with Remdesivir.]
[J05AE05, amprenavir, The metabolism of Selexipag can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may decrease the antihypertensive activities of Selexipag.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Selexipag.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Selexipag.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Selexipag.]
[N02CC06, eletriptan, Eletriptan may decrease the antihypertensive activities of Selexipag.]
[M01AH02, rofecoxib, The therapeutic efficacy of Selexipag can be decreased when used in combination with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Selexipag can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, Clevidipine may increase the hypotensive activities of Selexipag.]
[C01BD07, dronedarone, The metabolism of Selexipag can be decreased when combined with Dronedarone.]
[C02AA06, methoserpidine, Selexipag may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Selexipag which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Selexipag can be increased when it is combined with Capmatinib.]
[N04BX04, opicapone, Opicapone may increase the hypotensive activities of Selexipag.]
[C01CA14, dopexamine, Dopexamine may decrease the antihypertensive activities of Selexipag.]
[M01AC04, droxicam, The therapeutic efficacy of Selexipag can be decreased when used in combination with Droxicam.]
[L01EX19, ripretinib, The serum concentration of Selexipag can be increased when it is combined with Ripretinib.]
[L01EX22, selpercatinib, The serum concentration of Selexipag can be increased when it is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The therapeutic efficacy of Selexipag can be decreased when used in combination with Dexketoprofen.]
[C08CA17, levamlodipine, Levamlodipine may increase the hypotensive activities of Selexipag.]
[J05AX29, fostemsavir, The serum concentration of Fostemsavir can be increased when it is combined with Selexipag.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Selexipag.]
[L04AC19, satralizumab, The serum concentration of Selexipag can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Selexipag can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Selexipag can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Selexipag can be increased when used in combination with Chlorothiazide.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the antihypertensive activities of Selexipag.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the hypotensive activities of Selexipag.]
[V04CK02, cholecystokinin, The excretion of Selexipag can be decreased when combined with Cholecystokinin.]
[N02BA07, ethenzamide, The therapeutic efficacy of Selexipag can be decreased when used in combination with Ethenzamide.]
[M01AB08, etodolac, The therapeutic efficacy of Selexipag can be decreased when used in combination with Etodolac.]
[M02AA06, etofenamate, The therapeutic efficacy of Selexipag can be decreased when used in combination with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Selexipag can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Selexipag can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Selexipag.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Selexipag.]
[L04AD03, voclosporin, The serum concentration of Selexipag can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Selexipag can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, Vericiguat may increase the hypotensive activities of Selexipag.]
[L01EX21, tepotinib, The serum concentration of Selexipag can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Selexipag can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Selexipag.]
[M01AE05, fenbufen, The therapeutic efficacy of Selexipag can be decreased when used in combination with Fenbufen.]
[C01CA19, fenoldopam, Fenoldopam may increase the hypotensive activities of Selexipag.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Selexipag.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Selexipag.]
[R03CC15, formoterol, Formoterol may decrease the antihypertensive activities of Selexipag.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Selexipag.]
[N01AB05, trichloroethylene, Trichloroethylene may decrease the antihypertensive activities of Selexipag.]
[H04AA02, dasiglucagon, Selexipag may increase the hypotensive activities of Dasiglucagon.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Selexipag.]
[A02BA01, cimetidine, The metabolism of Selexipag can be decreased when combined with Cimetidine.]
[L01XX73, sotorasib, The serum concentration of Selexipag can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Selexipag can be decreased when combined with Ciprofloxacin.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Selexipag.]
[L04AA48, belumosudil, The serum concentration of Selexipag can be increased when it is combined with Belumosudil.]
[M01AG01, mefenamic acid, The therapeutic efficacy of Selexipag can be decreased when used in combination with Mefenamic acid.]
[R03CC13, clenbuterol, Clenbuterol may decrease the antihypertensive activities of Selexipag.]
[N06AX25, St. John's wort extract, The metabolism of Selexipag can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Selexipag can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Selexipag can be increased when it is combined with Maribavir.]
[D11AH08, abrocitinib, The serum concentration of Selexipag can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Selexipag can be increased when it is combined with Clofazimine.]
[B06AX04, mitapivat, The serum concentration of Selexipag can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the hypotensive activities of Selexipag.]
[L01EJ03, pacritinib, The serum concentration of Selexipag can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Selexipag can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, Clomipramine may decrease the antihypertensive activities of Selexipag.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Clonidine is combined with Selexipag.]
[C01EB24, mavacamten, The serum concentration of Selexipag can be decreased when it is combined with Mavacamten.]
[H01CC04, linzagolix, The serum concentration of Selexipag can be increased when it is combined with Linzagolix.]
[N05AH02, clozapine, The metabolism of Selexipag can be decreased when combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Selexipag.]
[A10BK06, sotagliflozin, The serum concentration of Selexipag can be increased when it is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Selexipag can be increased when combined with Somatrogon.]
[C02KB01, metyrosine, Metyrosine may increase the hypotensive activities of Selexipag.]
[L04AC21, bimekizumab, The metabolism of Selexipag can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The therapeutic efficacy of Selexipag can be decreased when used in combination with Proquazone.]
[M04AC01, colchicine, The serum concentration of Selexipag can be increased when it is combined with Colchicine.]
[N01AB07, desflurane, Desflurane may decrease the antihypertensive activities of Selexipag.]
[C04AX28, ifenprodil, Ifenprodil may decrease the antihypertensive activities of Selexipag.]
[N02BA16, imidazole-2-hydroxybenzoate, The therapeutic efficacy of Selexipag can be decreased when used in combination with Imidazole salicylate.]
[J01FA15, telithromycin, The metabolism of Selexipag can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The therapeutic efficacy of Selexipag can be decreased when used in combination with Indobufen.]
[M01AH03, valdecoxib, The therapeutic efficacy of Selexipag can be decreased when used in combination with Valdecoxib.]
[A03AX10, isometheptene, Isometheptene may decrease the antihypertensive activities of Selexipag.]
[N02CC05, almotriptan, The metabolism of Selexipag can be decreased when combined with Almotriptan.]
[M01AH04, parecoxib, The therapeutic efficacy of Selexipag can be decreased when used in combination with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Selexipag can be decreased when combined with Itraconazole.]
[M01AA06, kebuzone, The therapeutic efficacy of Selexipag can be decreased when used in combination with Kebuzone.]
[L01EA01, imatinib, The metabolism of Selexipag can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Selexipag can be decreased when combined with Posaconazole.]
[S01EE04, travoprost, Travoprost may increase the hypotensive activities of Selexipag.]
[S01EE03, bimatoprost, Bimatoprost may increase the hypotensive activities of Selexipag.]
[C08CA09, lacidipine, Lacidipine may increase the hypotensive activities of Selexipag.]
[N07BC04, lofexidine, Lofexidine may decrease the antihypertensive activities of Selexipag.]
[M01AB09, lonazolac, The therapeutic efficacy of Selexipag can be decreased when used in combination with Lonazolac.]
[R06AX13, loratadine, The metabolism of Selexipag can be decreased when combined with Loratadine.]
[M02AA31, loxoprofen, The therapeutic efficacy of Selexipag can be decreased when used in combination with Loxoprofen.]
[C09AA03, lisinopril, Lisinopril may increase the hypotensive activities of Selexipag.]
[C08CA11, manidipine, Manidipine may increase the hypotensive activities of Selexipag.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Selexipag.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the antihypertensive activities of Selexipag.]
[C03DA04, eplerenone, Eplerenone may increase the hypotensive activities of Selexipag.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Selexipag can be increased when used in combination with Cyclopenthiazide.]
[J05AF07, tenofovir disoproxil, The serum concentration of Selexipag can be increased when it is combined with Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The metabolism of Selexipag can be increased when combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the hypotensive activities of Selexipag.]
[S01XA18, cyclosporine, The metabolism of Selexipag can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Selexipag.]
[C09AA13, moexipril, Moexipril may increase the hypotensive activities of Selexipag.]
[C10AA07, rosuvastatin, The excretion of Selexipag can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The therapeutic efficacy of Selexipag can be decreased when used in combination with Mofebutazone.]
[M01AX22, morniflumate, The therapeutic efficacy of Selexipag can be decreased when used in combination with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Selexipag can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Moxonidine may decrease the antihypertensive activities of Selexipag.]
[G04BE09, vardenafil, The serum concentration of Selexipag can be increased when it is combined with Vardenafil.]
[M01AH05, etoricoxib, The therapeutic efficacy of Selexipag can be decreased when used in combination with Etoricoxib.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Selexipag.]
[G03XA01, danazol, The metabolism of Selexipag can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Selexipag can be decreased when combined with Dapsone.]
[C02CC04, debrisoquin, Debrisoquine may increase the hypotensive activities of Selexipag.]
[A04AD11, nabilone, Nabilone may increase the hypotensive activities of Selexipag.]
[M01AX01, nabumetone, The therapeutic efficacy of Selexipag can be decreased when used in combination with Nabumetone.]
[C07AB12, nebivolol, Nebivolol may increase the hypotensive activities of Selexipag.]
[N06AX06, nefazodone, The metabolism of Selexipag can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Selexipag.]
[L02BB02, nilutamide, The metabolism of Selexipag can be decreased when combined with Nilutamide.]
[C01CA23, theodrenaline, Theodrenaline may decrease the antihypertensive activities of Selexipag.]
[C01CA05, norfenefrine, Norfenefrine may decrease the antihypertensive activities of Selexipag.]
[G04BD08, solifenacin, Solifenacin may decrease the antihypertensive activities of Selexipag.]
[A07EC03, olsalazine, The therapeutic efficacy of Selexipag can be decreased when used in combination with Olsalazine.]
[N06AA01, desipramine, Desipramine may decrease the antihypertensive activities of Selexipag.]
[H01BA02, desmopressin, Desmopressin may decrease the antihypertensive activities of Selexipag.]
[C09XA02, aliskiren, Aliskiren may increase the hypotensive activities of Selexipag.]
[M01AE12, oxaprozin, The therapeutic efficacy of Selexipag can be decreased when used in combination with Oxaprozin.]
[S03BA01, dexamethasone, The metabolism of Selexipag can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Selexipag can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Selexipag can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the antihypertensive activities of Selexipag.]
[N03AC01, paramethadione, The metabolism of Selexipag can be decreased when combined with Paramethadione.]
[B01AC04, clopidogrel, The metabolism of Selexipag can be decreased when combined with Clopidogrel.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Selexipag.]
[N06AA08, dibenzepin, Dibenzepin may decrease the antihypertensive activities of Selexipag.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the hypotensive activities of Selexipag.]
[S01BC03, diclofenac, The therapeutic efficacy of Selexipag can be decreased when used in combination with Diclofenac.]
[C02DG01, pinacidil, Pinacidil may increase the hypotensive activities of Selexipag.]
[A10BG03, pioglitazone, The metabolism of Selexipag can be decreased when combined with Pioglitazone.]
[N05AD05, pipamperone, Pipamperone may increase the hypotensive activities of Selexipag.]
[L01DC04, ixabepilone, The serum concentration of Selexipag can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Selexipag.]
[R03CC07, pirbuterol, Pirbuterol may decrease the antihypertensive activities of Selexipag.]
[A08AA03, diethylpropion, Diethylpropion may decrease the antihypertensive activities of Selexipag.]
[L02AA01, diethylstilbestrol, The metabolism of Selexipag can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Selexipag can be decreased when combined with Isradipine.]
[N02BA11, diflunisal, The therapeutic efficacy of Selexipag can be decreased when used in combination with Diflunisal.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Selexipag.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Selexipag.]
[C02DB01, dihydralazine, Selexipag may increase the hypotensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may decrease the antihypertensive activities of Selexipag.]
[N02CA01, dihydroergotamine, Dihydroergotamine may decrease the antihypertensive activities of Selexipag.]
[J05AE08, atazanavir, The metabolism of Selexipag can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Treprostinil may increase the hypotensive activities of Selexipag.]
[C08DB01, diltiazem, The metabolism of Selexipag can be decreased when combined with Diltiazem.]
[R03CC08, procaterol, Procaterol may decrease the antihypertensive activities of Selexipag.]
[N02BB04, propyphenazone, The therapeutic efficacy of Selexipag can be decreased when used in combination with Propyphenazone.]
[M01AB14, proglumetacin, The therapeutic efficacy of Selexipag can be decreased when used in combination with Proglumetacin.]
[C05CA03, diosmin, The serum concentration of Selexipag can be increased when it is combined with Diosmin.]
[C09AA06, quinapril, Quinapril may increase the hypotensive activities of Selexipag.]
[B01AC07, dipyridamole, Dipyridamole may increase the antihypertensive activities of Selexipag.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Selexipag.]
[N06AA23, quinupramine, Quinupramine may decrease the antihypertensive activities of Selexipag.]
[A03FA02, cisapride, The metabolism of Selexipag can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Ramipril may increase the hypotensive activities of Selexipag.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Selexipag.]
[R03CC14, reproterol, Reproterol may decrease the antihypertensive activities of Selexipag.]
[S02AA12, rifamycin SV, The metabolism of Selexipag can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Selexipag can be increased when combined with Rifapentine.]
[N05AX08, risperidone, Risperidone may decrease the antihypertensive activities of Selexipag.]
[N01BB09, ropivacaine, Ropivacaine may increase the hypotensive activities of Selexipag.]
[A04AD12, aprepitant, The metabolism of Selexipag can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Selexipag.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Selexipag.]
[G04BE08, tadalafil, Tadalafil may increase the hypotensive activities of Selexipag.]
[S01BC05, ketorolac, The therapeutic efficacy of Selexipag can be decreased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, The serum concentration of Selexipag can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Selexipag can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The therapeutic efficacy of Selexipag can be decreased when used in combination with Salsalate.]
[R03AC12, salmeterol, The metabolism of Selexipag can be decreased when combined with Salmeterol.]
[C01CA07, dobutamine, Dobutamine may decrease the antihypertensive activities of Selexipag.]
[A03FA03, domperidone, The metabolism of Selexipag can be decreased when combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the antihypertensive activities of Selexipag.]
[N06AA16, dothiepin, Dosulepin may decrease the antihypertensive activities of Selexipag.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Selexipag.]
[N06AA12, doxepin, Doxepin may decrease the antihypertensive activities of Selexipag.]
[N01AB08, sevoflurane, Sevoflurane may decrease the antihypertensive activities of Selexipag.]
[N05AD08, droperidol, Droperidol may decrease the antihypertensive activities of Selexipag.]
[C10AA01, simvastatin, The serum concentration of Selexipag can be increased when it is combined with Simvastatin.]
[C09AA11, spirapril, Spirapril may increase the hypotensive activities of Selexipag.]
[N02CC01, sumatriptan, Sumatriptan may decrease the antihypertensive activities of Selexipag.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Selexipag.]
[M01AC02, tenoxicam, The therapeutic efficacy of Selexipag can be decreased when used in combination with Tenoxicam.]
[G04CA03, terazosin, Terazosin may increase the hypotensive activities of Selexipag.]
[D01BA02, terbinafine, The metabolism of Selexipag can be decreased when combined with Terbinafine.]
[S01GA02, tetrahydrozoline, Tetryzoline may decrease the antihypertensive activities of Selexipag.]
[N06AX14, tianeptine, Tianeptine may decrease the antihypertensive activities of Selexipag.]
[C09AA02, enalapril, Enalapril may increase the hypotensive activities of Selexipag.]
[M01AG02, tolfenamic acid, The therapeutic efficacy of Selexipag can be decreased when used in combination with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Selexipag.]
[N06BA09, atomoxetine, Atomoxetine may decrease the antihypertensive activities of Selexipag.]
[L02BA02, toremifene, The serum concentration of Selexipag can be increased when it is combined with Toremifene.]
[C03CA04, torsemide, The metabolism of Selexipag can be decreased when combined with Torasemide.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Selexipag.]
[C09AA10, trandolapril, Trandolapril may increase the hypotensive activities of Selexipag.]
[R03CC11, tulobuterol, Tulobuterol may decrease the antihypertensive activities of Selexipag.]
[C02CA06, urapidil, Urapidil may decrease the antihypertensive activities of Selexipag.]
[S01FB02, ephedrine, Ephedrine may decrease the antihypertensive activities of Selexipag.]
[C01CX07, xamoterol, Xamoterol may decrease the antihypertensive activities of Selexipag.]
[S01GA03, xylometazoline, Xylometazoline may decrease the antihypertensive activities of Selexipag.]
[C08CA12, mepirodipine, Selexipag may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, Epinephrine may decrease the antihypertensive activities of Selexipag.]
[C09AA15, zofenopril, Selexipag may increase the hypotensive activities of Zofenopril.]
[M01AB04, zomepirac, The therapeutic efficacy of Selexipag can be decreased when used in combination with Zomepirac.]
[N03AX15, zonisamide, The serum concentration of Selexipag can be increased when it is combined with Zonisamide.]
[N05CF01, zopiclone, The metabolism of Selexipag can be decreased when combined with Zopiclone.]
[C02AC02, guanfacine, Guanfacine may decrease the antihypertensive activities of Selexipag.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Selexipag.]
[G02AB03, ergonovine, Ergometrine may decrease the antihypertensive activities of Selexipag.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may decrease the antihypertensive activities of Selexipag.]
[N02CA02, ergotamine, The metabolism of Selexipag can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Selexipag can be decreased when combined with Erythromycin.]
[A02BC02, pantoprazole, The excretion of Selexipag can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, The metabolism of Selexipag can be decreased when combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The excretion of Selexipag can be decreased when combined with Conjugated estrogens.]
[R03BA09, fluticasone furoate, The metabolism of Selexipag can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Selexipag can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Selexipag can be decreased when combined with Fluvastatin.]
[C01CA15, gepefrine, Gepefrine may decrease the antihypertensive activities of Selexipag.]
[L02AA03, ethinyl estradiol, The metabolism of Selexipag can be decreased when combined with Ethinylestradiol.]
[V03AF05, amifostine, Selexipag may increase the hypotensive activities of Amifostine.]
[M01AC06, meloxicam, The therapeutic efficacy of Selexipag can be decreased when used in combination with Meloxicam.]
[C01CA01, etilefrine, Etilefrine may decrease the antihypertensive activities of Selexipag.]
[N01AX07, etomidate, Etomidate may decrease the antihypertensive activities of Selexipag.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Selexipag.]
[L04AD02, tacrolimus, The serum concentration of Selexipag can be increased when it is combined with Tacrolimus.]
[R06AX12, terfenadine, The metabolism of Selexipag can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Selexipag can be decreased when combined with Fluvoxamine.]
[C10AA03, pravastatin, The serum concentration of Selexipag can be increased when it is combined with Pravastatin.]
[A16AA01, levocarnitine, The excretion of Selexipag can be decreased when combined with Levocarnitine.]
[C08CA02, felodipine, The metabolism of Selexipag can be decreased when combined with Felodipine.]
[M01AE04, fenoprofen, The therapeutic efficacy of Selexipag can be decreased when used in combination with Fenoprofen.]
[R03CC04, fenoterol, Fenoterol may decrease the antihypertensive activities of Selexipag.]
[N02AB03, fentanyl, Fentanyl may decrease the antihypertensive activities of Selexipag.]
[R03CC02, albuterol, Salbutamol may decrease the antihypertensive activities of Selexipag.]
[L01BB06, clofarabine, Clofarabine may increase the hypotensive activities of Selexipag.]
[N02BG04, floctafenine, The therapeutic efficacy of Selexipag can be decreased when used in combination with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Selexipag can be decreased when combined with Fluconazole.]
[N06AA14, melitracen, Melitracen may decrease the antihypertensive activities of Selexipag.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Selexipag.]
[N05AF01, flupenthixol, Flupentixol may decrease the antihypertensive activities of Selexipag.]
[S01BC04, flurbiprofen, The therapeutic efficacy of Selexipag can be decreased when used in combination with Flurbiprofen.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Selexipag.]
[N06BX17, adrafinil, Adrafinil may decrease the antihypertensive activities of Selexipag.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Selexipag.]
[J05AE10, darunavir, The metabolism of Selexipag can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the hypotensive activities of Selexipag.]
[N05CF04, eszopiclone, The metabolism of Selexipag can be decreased when combined with Eszopiclone.]
[C10AB04, gemfibrozil, The serum concentration of Selexipag can be increased when it is combined with Gemfibrozil.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Selexipag.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Selexipag.]
[N01AH02, alfentanil, Alfentanil may decrease the antihypertensive activities of Selexipag.]
[L01EH01, lapatinib, The serum concentration of Selexipag can be increased when it is combined with Lapatinib.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the antihypertensive activities of Selexipag.]
[C05AE01, nitroglycerin, Nitroglycerin may increase the hypotensive activities of Selexipag.]
[C02CA04, doxazosin, Doxazosin may increase the hypotensive activities of Selexipag.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Selexipag.]
[C07AB09, esmolol, Esmolol may increase the hypotensive activities of Selexipag.]
[C09AA09, fosinopril, Fosinopril may increase the hypotensive activities of Selexipag.]
[S01EX01, guanethidine, Guanethidine may increase the hypotensive activities of Selexipag.]
[P01BX01, halofantrine, The metabolism of Selexipag can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Selexipag.]
[N01AB01, halothane, Halothane may decrease the antihypertensive activities of Selexipag.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Selexipag.]
[L01CE02, irinotecan, The excretion of Selexipag can be decreased when combined with Irinotecan.]
[C09CA01, losartan, The metabolism of Selexipag can be decreased when combined with Losartan.]
[A07EC02, mesalamine, The therapeutic efficacy of Selexipag can be decreased when used in combination with Mesalazine.]
[R03CC05, hexoprenaline, Hexoprenaline may decrease the antihypertensive activities of Selexipag.]
[C08CA10, nilvadipine, The metabolism of Selexipag can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The therapeutic efficacy of Selexipag can be decreased when used in combination with Nimesulide.]
[C09AA04, perindopril, Perindopril may increase the hypotensive activities of Selexipag.]
[C02DB02, hydralazine, Hydralazine may increase the hypotensive activities of Selexipag.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Selexipag can be increased when used in combination with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The metabolism of Selexipag can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Selexipag can be increased when used in combination with Hydroflumethiazide.]
[G04BD06, propiverine, Propiverine may decrease the antihypertensive activities of Selexipag.]
[P01BA02, hydroxychloroquine, The metabolism of Selexipag can be decreased when combined with Hydroxychloroquine.]
[J04AB04, rifabutin, The metabolism of Selexipag can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Rilmenidine may decrease the antihypertensive activities of Selexipag.]
[R02AX02, ibuprofen, The therapeutic efficacy of Selexipag can be decreased when used in combination with Ibuprofen.]
[L01AA06, ifosfamide, The metabolism of Selexipag can be increased when combined with Ifosfamide.]
[N01AH03, sufentanil, Sufentanil may decrease the antihypertensive activities of Selexipag.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Selexipag.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Selexipag.]
[M03BX02, tizanidine, Tizanidine may increase the hypotensive activities of Selexipag.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Selexipag.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Selexipag.]
[S01BC01, indomethacin, The therapeutic efficacy of Selexipag can be decreased when used in combination with Indomethacin.]
[C02CA02, indoramin, Indoramin may decrease the antihypertensive activities of Selexipag.]
[N06AX17, milnacipran, The metabolism of Selexipag can be decreased when combined with Milnacipran.]
[A10BH01, sitagliptin, The metabolism of Selexipag can be decreased when combined with Sitagliptin.]
[C10AA06, cerivastatin, The metabolism of Selexipag can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, Alprenolol may increase the hypotensive activities of Selexipag.]
[N06AA13, iprindole, Iprindole may decrease the antihypertensive activities of Selexipag.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Selexipag.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Selexipag.]
[S01EC03, dorzolamide, Dorzolamide may increase the hypotensive activities of Selexipag.]
[R03CC06, isoetharine, Isoetharine may decrease the antihypertensive activities of Selexipag.]
[C09AA16, imidapril, Selexipag may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may decrease the antihypertensive activities of Selexipag.]
[J04AC01, isoniazid, The metabolism of Selexipag can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, Isoprenaline may decrease the antihypertensive activities of Selexipag.]
[C01DA14, isosorbide mononitrate, Selexipag may increase the vasodilatory activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, Isosorbide dinitrate may increase the hypotensive activities of Selexipag.]
[C04AA01, isoxsuprine, Isoxsuprine may decrease the antihypertensive activities of Selexipag.]
[P02CF01, ivermectin, The excretion of Selexipag can be decreased when combined with Ivermectin.]
[L04AC07, tocilizumab, The metabolism of Selexipag can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Selexipag can be decreased when combined with Ketamine.]
[C02KD01, ketanserin, Selexipag may increase the hypotensive activities of Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Selexipag can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Selexipag can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the hypotensive activities of Selexipag.]
[M02AA10, ketoprofen, The therapeutic efficacy of Selexipag can be decreased when used in combination with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Selexipag can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Selexipag can be increased when combined with Abatacept.]
[C01CA22, arbutamine, Arbutamine may decrease the antihypertensive activities of Selexipag.]
[N04BC09, rotigotine, Rotigotine may decrease the antihypertensive activities of Selexipag.]
[M01AE11, tiaprofenic acid, The therapeutic efficacy of Selexipag can be decreased when used in combination with Tiaprofenic acid.]
[C07AG01, labetalol, Labetalol may increase the hypotensive activities of Selexipag.]
[C02AA05, deserpidine, Deserpidine may increase the hypotensive activities of Selexipag.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the hypotensive activities of Selexipag.]
[N04BA01, levodopa, Levodopa may increase the hypotensive activities of Selexipag.]
[C03DB01, amiloride, Amiloride may increase the hypotensive activities of Selexipag.]
[N02CA07, lisuride, Lisuride may decrease the antihypertensive activities of Selexipag.]
[N06AA07, lofepramine, Lofepramine may decrease the antihypertensive activities of Selexipag.]
[A07DA03, loperamide, The metabolism of Selexipag can be decreased when combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Selexipag can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The serum concentration of Selexipag can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Selexipag can be increased when it is combined with Temsirolimus.]
[L01EA03, nilotinib, The metabolism of Selexipag can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Selexipag can be increased when it is combined with Mannitol.]
[C02BB01, mecamylamine, Mecamylamine may increase the hypotensive activities of Selexipag.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Selexipag can be decreased when used in combination with Meclofenamic acid.]
[P01BC02, mefloquine, The serum concentration of Selexipag can be increased when it is combined with Mefloquine.]
[C01CA11, mephentermine, Mephentermine may decrease the antihypertensive activities of Selexipag.]
[N03AB04, mephenytoin, The metabolism of Selexipag can be decreased when combined with Mephenytoin.]
[N05AX13, paliperidone, The serum concentration of Selexipag can be increased when it is combined with Paliperidone.]
[C01CA09, metaraminol, Metaraminol may decrease the antihypertensive activities of Selexipag.]
[N06BA03, methamphetamine, Metamfetamine may decrease the antihypertensive activities of Selexipag.]
[S01EC05, methazolamide, Methazolamide may increase the hypotensive activities of Selexipag.]
[G02CB05, metergoline, Metergoline may decrease the antihypertensive activities of Selexipag.]
[H03BB02, methimazole, The metabolism of Selexipag can be decreased when combined with Methimazole.]
[N05AA02, methotrimeprazine, Methotrimeprazine may decrease the antihypertensive activities of Selexipag.]
[C01CA10, methoxamine, Methoxamine may decrease the antihypertensive activities of Selexipag.]
[N02BG09, methoxyflurane, Methoxyflurane may decrease the antihypertensive activities of Selexipag.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Selexipag can be increased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, Methyldopa may increase the hypotensive activities of Selexipag.]
[V04CG05, methylene blue, Methylene blue may increase the hypotensive activities of Selexipag.]
[G02AB01, methylergonovine, Methylergometrine may decrease the antihypertensive activities of Selexipag.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Selexipag.]
[N02CA04, methysergide, Methysergide may decrease the antihypertensive activities of Selexipag.]
[C03BA08, metolazone, Metolazone may increase the hypotensive activities of Selexipag.]
[C07AB02, metoprolol, Metoprolol may increase the hypotensive activities of Selexipag.]
[P01AB01, metronidazole, The metabolism of Selexipag can be decreased when combined with Metronidazole.]
[N06AX03, mianserin, Mianserin may decrease the antihypertensive activities of Selexipag.]
[S02AA13, miconazole, The metabolism of Selexipag can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The therapeutic efficacy of Selexipag can be decreased when used in combination with Aminophenazone.]
[C01CA17, midodrine, Midodrine may decrease the antihypertensive activities of Selexipag.]
[G03XB01, mifepristone, The serum concentration of Selexipag can be increased when it is combined with Mifepristone.]
[C09CA03, valsartan, Valsartan may increase the hypotensive activities of Selexipag.]
[D11AX01, minoxidil, Minoxidil may increase the hypotensive activities of Selexipag.]
[L01XX23, mitotane, The metabolism of Selexipag can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the antihypertensive activities of Selexipag.]
[L03AC01, aldesleukin, Aldesleukin may increase the hypotensive activities of Selexipag.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Selexipag.]
[C01BD01, amiodarone, The metabolism of Selexipag can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Selexipag can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The metabolism of Selexipag can be decreased when combined with Morphine.]
[L04AB05, certolizumab pegol, The metabolism of Selexipag can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Selexipag can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Selexipag.]
[P01BA06, amodiaquine, The metabolism of Selexipag can be decreased when combined with Amodiaquine.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Selexipag is combined with Silodosin.]
[G03XC01, raloxifene, The metabolism of Selexipag can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Amoxapine may decrease the antihypertensive activities of Selexipag.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Selexipag.]
[C07AA12, nadolol, Nadolol may increase the hypotensive activities of Selexipag.]
[N04BC04, ropinirole, Ropinirole may increase the hypotensive activities of Selexipag.]
[V03AB15, naloxone, The metabolism of Selexipag can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Selexipag can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Naphazoline may decrease the antihypertensive activities of Selexipag.]
[N06BA01, amphetamine, Amphetamine may decrease the antihypertensive activities of Selexipag.]
[M02AA12, naproxen, The therapeutic efficacy of Selexipag can be decreased when used in combination with Naproxen.]
[A10BG01, troglitazone, The metabolism of Selexipag can be decreased when combined with Troglitazone.]
[N04BX01, tolcapone, Tolcapone may increase the hypotensive activities of Selexipag.]
[N01AH06, remifentanil, Remifentanil may decrease the antihypertensive activities of Selexipag.]
[A10BX02, repaglinide, The metabolism of Selexipag can be decreased when combined with Repaglinide.]
[C01CX08, levosimendan, Levosimendan may increase the hypotensive activities of Selexipag.]
[N05AX14, iloperidone, Iloperidone may decrease the antihypertensive activities of Selexipag.]
[J02AA01, amphotericin B, Amphotericin B may increase the hypotensive activities of Selexipag.]
[N06AX23, desvenlafaxine, The metabolism of Selexipag can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Telmisartan may increase the hypotensive activities of Selexipag.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Selexipag.]
[C08CA04, nicardipine, The metabolism of Selexipag can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may decrease the antihypertensive activities of Selexipag.]
[C08CA05, nifedipine, Nifedipine may increase the hypotensive activities of Selexipag.]
[M02AA17, niflumic acid, The therapeutic efficacy of Selexipag can be decreased when used in combination with Niflumic acid.]
[V03AB22, amyl nitrite, Amyl Nitrite may increase the hypotensive activities of Selexipag.]
[C08CA06, nimodipine, Nimodipine may increase the hypotensive activities of Selexipag.]
[C08CA07, nisoldipine, Nisoldipine may increase the hypotensive activities of Selexipag.]
[C08CA08, nitrendipine, Nitrendipine may increase the hypotensive activities of Selexipag.]
[R07AX01, nitric oxide, Nitric Oxide may increase the hypotensive activities of Selexipag.]
[N04BC05, pramipexole, Pramipexole may increase the hypotensive activities of Selexipag.]
[C02DD01, nitroprusside, Nitroprusside may increase the hypotensive activities of Selexipag.]
[N01AX13, nitrous oxide, Nitrous oxide may decrease the antihypertensive activities of Selexipag.]
[C01CA03, norepinephrine, Norepinephrine may decrease the antihypertensive activities of Selexipag.]
[C02KX01, bosentan, Bosentan may increase the hypotensive activities of Selexipag.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Selexipag.]
[A16AX07, sapropterin, The serum concentration of Selexipag can be increased when it is combined with Sapropterin.]
[G02CA02, nylidrin, Nylidrin may decrease the antihypertensive activities of Selexipag.]
[G01AA01, nystatin, The excretion of Selexipag can be decreased when combined with Nystatin.]
[L04AC04, rilonacept, The metabolism of Selexipag can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Selexipag can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, Opipramol may decrease the antihypertensive activities of Selexipag.]
[R03CB03, metaproterenol, Orciprenaline may decrease the antihypertensive activities of Selexipag.]
[G04CA02, tamsulosin, Tamsulosin may increase the hypotensive activities of Selexipag.]
[C01AC01, ouabain, The excretion of Selexipag can be decreased when combined with Ouabain.]
[C07AA02, oxprenolol, Oxprenolol may increase the hypotensive activities of Selexipag.]
[C01DX03, oxyfedrine, Oxyfedrine may decrease the antihypertensive activities of Selexipag.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Selexipag can be decreased when used in combination with Oxymetazoline.]
[S01BC02, oxyphenbutazone, The therapeutic efficacy of Selexipag can be decreased when used in combination with Oxyphenbutazone.]
[V04CH30, 4-aminohippuric acid, The excretion of Selexipag can be decreased when combined with Aminohippuric acid.]
[N05AH05, asenapine, Asenapine may decrease the antihypertensive activities of Selexipag.]
[G04BE02, papaverine, Papaverine may increase the hypotensive activities of Selexipag.]
[C02KC01, pargyline, Pargyline may increase the hypotensive activities of Selexipag.]
[C07AA23, penbutolol, Penbutolol may increase the hypotensive activities of Selexipag.]
[N05CA01, pentobarbital, The metabolism of Selexipag can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Selexipag.]
[N04BC02, pergolide, Pergolide may decrease the antihypertensive activities of Selexipag.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Selexipag.]
[N03AA02, phenobarbital, The metabolism of Selexipag can be increased when combined with Phenobarbital.]
[C04AX02, phenoxybenzamine, Phenoxybenzamine may decrease the antihypertensive activities of Selexipag.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Selexipag.]
[A08AA01, phentermine, Phentermine may decrease the antihypertensive activities of Selexipag.]
[V03AB36, phentolamine, Phentolamine may decrease the antihypertensive activities of Selexipag.]
[M02AA01, phenylbutazone, The therapeutic efficacy of Selexipag can be decreased when used in combination with Phenylbutazone.]
[S01GA05, phenylephrine, Phenylephrine may decrease the antihypertensive activities of Selexipag.]
[R01BA01, phenylpropanolamine, Phenylpropanolamine may decrease the antihypertensive activities of Selexipag.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Selexipag.]
[L04AB06, golimumab, The metabolism of Selexipag can be increased when combined with Golimumab.]
[C08CX01, mibefradil, The serum concentration of Selexipag can be increased when it is combined with Mibefradil.]
[C07AA03, pindolol, Pindolol may increase the hypotensive activities of Selexipag.]
[C10AA05, atorvastatin, The metabolism of Selexipag can be decreased when combined with Atorvastatin.]
[J05AE01, saquinavir, The metabolism of Selexipag can be decreased when combined with Saquinavir.]
[C09CA02, eprosartan, Eprosartan may increase the hypotensive activities of Selexipag.]
[S01BC06, piroxicam, The therapeutic efficacy of Selexipag can be decreased when used in combination with Piroxicam.]
[N02CX01, pizotyline, Pizotifen may decrease the antihypertensive activities of Selexipag.]
[J05AG02, delavirdine, The metabolism of Selexipag can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Selexipag can be decreased when combined with Irbesartan.]
[D05AX05, tazarotene, The metabolism of Selexipag can be decreased when combined with Tazarotene.]
[A10BG02, rosiglitazone, The metabolism of Selexipag can be decreased when combined with Rosiglitazone.]
[L02BG03, anastrozole, The metabolism of Selexipag can be decreased when combined with Anastrozole.]
[L04AC08, canakinumab, The metabolism of Selexipag can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Selexipag can be increased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Selexipag can be increased when it is combined with Ritonavir.]
[C10AA08, pitavastatin, The metabolism of Selexipag can be decreased when combined with Pitavastatin.]
[C07AB01, practolol, Practolol may increase the hypotensive activities of Selexipag.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Selexipag.]
[P01BA03, primaquine, The metabolism of Selexipag can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Selexipag can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Selexipag can be increased when combined with Probenecid.]
[S01HA05, procaine, Procaine may increase the hypotensive activities of Selexipag.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Selexipag.]
[C10AB05, fenofibrate, The metabolism of Selexipag can be decreased when combined with Fenofibrate.]
[G03DA04, progesterone, The excretion of Selexipag can be decreased when combined with Progesterone.]
[N05AA03, promazine, Promazine may decrease the antihypertensive activities of Selexipag.]
[C01BC03, propafenone, The serum concentration of Selexipag can be increased when it is combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Selexipag can be increased when it is combined with Fexofenadine.]
[N05AC01, periciazine, Periciazine may decrease the antihypertensive activities of Selexipag.]
[N05CM06, propiomazine, Propiomazine may decrease the antihypertensive activities of Selexipag.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Selexipag.]
[N01AX10, propofol, The metabolism of Selexipag can be decreased when combined with Propofol.]
[C07AA05, propranolol, Propranolol may increase the hypotensive activities of Selexipag.]
[N02CC04, rizatriptan, Rizatriptan may decrease the antihypertensive activities of Selexipag.]
[B01AC09, epoprostenol, Epoprostenol may increase the hypotensive activities of Selexipag.]
[R03DC03, montelukast, The metabolism of Selexipag can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, Protriptyline may decrease the antihypertensive activities of Selexipag.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the antihypertensive activities of Selexipag.]
[N05AX12, aripiprazole, The risk or severity of hypotension can be increased when Aripiprazole is combined with Selexipag.]
[P01BD01, pyrimethamine, The metabolism of Selexipag can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The serum concentration of Selexipag can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The metabolism of Selexipag can be decreased when combined with Quinine.]
[C02AA01, rescinnamine, Rescinnamine may decrease the antihypertensive activities of Selexipag.]
[C02AA02, reserpine, The serum concentration of Selexipag can be increased when it is combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Selexipag can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, Rimiterol may decrease the antihypertensive activities of Selexipag.]
[G02CA01, ritodrine, Ritodrine may decrease the antihypertensive activities of Selexipag.]
[J01FA06, roxithromycin, The excretion of Selexipag can be decreased when combined with Roxithromycin.]
[N02BA05, salicylamide, The therapeutic efficacy of Selexipag can be decreased when used in combination with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Selexipag can be decreased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Selexipag can be decreased when used in combination with Salicylic acid.]
[N05CA06, secobarbital, The metabolism of Selexipag can be increased when combined with Secobarbital.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Selexipag.]
[L01FA03, obinutuzumab, Selexipag may increase the hypotensive activities of Obinutuzumab.]
[C07AA07, sotalol, Sotalol may increase the hypotensive activities of Selexipag.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Selexipag.]
[C03DA01, spironolactone, The metabolism of Selexipag can be decreased when combined with Spironolactone.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Selexipag.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Selexipag can be increased when it is combined with Technetium Tc-99m sestamibi.]
